RETROSPECTIVE EFFICACY ANALYSIS OF ACUTE VASOREACTIVE TEST AS A CRITERIA FOR SURGERY IN CHILDREN WITH INBORN LEFT-TO-RIGHT BLOOD SHUNTING AND PULMONARY ARTERIAL HYPERTENSION

Aim. Retrospective analysis of efficacy of the acute vasoreactive test (AVRT) as a criteria for operability of children with inborn left-to-right blood shunting complicated by pulmonary arterial hypertension (IRLBS-PAH), by an experience of one center.

Material and methods. Retrospective analysis of the data of right heart chambers catheterization and echocardiographic study from 29 case histories of BS-PAH patients during 2012-2016. Results of AVRT are interpreted by modified Barst criteria (decline of pulmonary vascular resistance index, PVRI, and relation of PVRI to the index of systemic vascular resistance, SVR more than 20%, and the and PVRI <6 Wood units/m2 in PVR/SVR <0,3). In accordance with the results of AVRT, patients were selected to two main groups: group 1 — children with positive response, group 2 — children with negative response. After correction of the inborn defect in bith groups, following assessment of cardiovascular system condition was done by echocardiographical study in one week and one month. Metrics of echocardiography data was indexed. For the defect of interventricular septum (DIVS), indexation of the size was done via the relation to aortic root diameter, that was measured in parasternal position, longitudinal axis. Systolic pressure in the right ventricle was measured by the velocity of tricuspid regurgitation, measured in apical four-chamber position. Mean values with the standard deviation and p-values were calculated in R studio 2017 software, v.1.0.153.

Results. Among 29 patients, girls to boys relation was 4,8:1. Mean age 6,0±4,9 y. o. For group 1: median of DIVS 1,4 with the value of additional shunting 9,93±9,39 mm, baseline systolic pressure in the right ventricle (SPRV) 57,96±20,16 mmHg, in one month after surgery 38,96±14,16 mmHg. No complications registered. In the second group, median DIVS 0,4 with additional shunting 3,3±0 mm. Baseline SPRV 66,05±17,27 mmHg, with the decline in one month after transcatheter closure to 57,4±17,35 mmHg. During the early post-surgery period, in 2 patients of group 2 there was pulmonary crisis, treated with inhalatory iloprost.

 Conclusion. Acute vasoreactive test is effective criteria of operability assessment of inborn left-to-right blood shunting, complicated by pulmonary arterial hypertension, in pediatrics.

1. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT), Eur. Heart J. 2015;ehv317. doi:10.1093/eurheartj/ehv317.

2. Apitz C, Hansmann G, Schranz D. Hemodynamic assessment and acute pulmonary vasoreactivity testing in the evaluation of children with pulmonary vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart Br. Card. Soc. 2016;102:2:ii23-29. doi:10.1136/heartjnl-2014-307340.

3. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005 Jun;111:23:3105-11. doi:10.1161/CIRCULATIONAHA.104.488486.

4. Barst RJ. Pulmonary arterial hypertension: diagnosis and evidence-based treatment. Chichester, England; Hoboken, NJ: John Wiley & Sons, 2008. ISBN 978-0-470-05972-2.

5. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study, Ann. Intern. Med. 1987;107,2:216-23.

6. Gu H, Li Q, Zhang Ch, et al. Inhaled iloprost during acute pulmonary vasodilator testing for preoperative assessment of surgical operability of congenital heart disease with severe pulmonary hypertension. Zhonghua Wai Ke Za Zhi. 2010;48,10:727-30.

7. Regression Equations for Calculation of Z Scores of Cardiac Structures in a Large Cohort of Healthy Infants, Children, and Adolescents: An Echocardiographic Study — Journal of the American Society of Echocardiography. http://www.onlinejase.com/article/S08947317(08)00119-3/fulltext (Accessed: 24-Jan-2018).

8. Barst RJ, Ivy DD, Foreman AJ, et al. Fourand seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL Registry). Am. J. Cardiol. 2014;113,1:147-55. doi:10.1016/j.amjcard.2013.09.032.

9. Hallioglu O, Dilber E, Celiker A. Comparison of acute hemodynamic effects of aerosolized and intravenous iloprost in secondary pulmonary hypertension in children with congenital heart disease. Am. J. Cardiol. 2003;92,8:1007-9.

10. Sung KW, Jeon YB, Kim NY, et al. The effects of perioperative inhaled iloprost on pulmonary hypertension with congenital heart disease. Cardiology. 2013;126,4:224-9. doi:10.1159/000354248.

11. Muller M, Scholz S, Maxeiner H, et al. Efficacy of inhaled iloprost in the management of pulmonary hypertension after cardiopulmonary bypass in infants undergoing congenital heart surgery. A case series of 31 patients. HSR Proc. Intensive Care Cardiovasc. Anesth. 2011;3,2:123-30.

12. Ivy DD, Doran AK, Smith KJ, et al. Shortand long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2008;51,2:161-9. doi:10.1016/j.jacc.2007.09.031.

13. Muller M, Scholz S, Kwapisz M, et al. Use of inhaled iloprost in a case of pulmonary hypertension during pediatric congenital heart surgery. Anesthesiology. 2003;99,3:743-4.

14. Vorhies EE, Caruthers RL, Rosenberg H, et al. Use of Inhaled Iloprost for the Management of Postoperative Pulmonary Hypertension in Congenital Heart Surgery Patients: Review of a Transition Protocol. Pediatr. Cardiol. 2014;35,8:1337-43. doi:10.1007/s00246-0140933-3.